Literature DB >> 16454991

A novel CFTR mutation found in a Chinese patient with cystic fibrosis.

Nan Li1, Pei Pei, Ding-fang Bu, Bing He, Guang-fa Wang.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is rare in Chinese. We investigated the mutations in the gene of cystic fibrosis transmembrane conductance regulator (CFTR) in a Chinese CF patient and reviewed the clinical features, gene mutations in Chinese CF cases.
METHODS: Blood samples were collected from a previously reported CF girl and her parents. The 24 coding exons of CFTR of the proband were amplified and sequenced.
RESULTS: A Chinese girl of 16 years old was diagnosed as CF at the age of 14. She had recurrent productive cough with bronchiectasis in bilateral upper lobes, parasinusitis and otitis media, but without pancreatic involvement. Her sweat chloride was (108.9 +/- 3.3) mmol/L. A heterozygous novel missense mutation of 699 C --> A which results in the amino acid change of N189K was identified in exon 5. In addition, a heterozygous 3821 - 3823 delT mutation in exon 19 was found in CFTR. The mutation 699C --> A was inherited from her father, and the 3821 - 3823 delT mutation was from her mother. Twenty patients with CF in Chinese reported from 1974 to 2004 were also reviewed. DelF508 mutation was not found in the nine cases whose CFTR mutations were analyzed.
CONCLUSIONS: The CF proband carries two heterozygous mutations (699C --> A and 3821 - 3823 delT) in CFTR. 699C --> A mutation is a novel mutation which is not reported previously. Review of reported Chinese cases suggests that the genotype of Chinese CF may be different from those of white cases. More studies are needed to understand the spectra of CFTR and clinical CF features in Chinese.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454991     DOI: 10.3901/jme.2006.11.103

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  8 in total

Review 1.  Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.

Authors:  Frédéric Becq
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

2.  The CFTR polymorphisms poly-T, TG-repeats and M470V in Chinese males with congenital bilateral absence of the vas deferens.

Authors:  Wu-Hua Ni; Lei Jiang; Qian-Jin Fei; Jian-Yuan Jin; Xu Yang; Xue-Feng Huang
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

3.  Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis.

Authors:  Q Qi; T Li; J C Li; Y Li
Journal:  Braz J Med Biol Res       Date:  2015-07-10       Impact factor: 2.590

4.  p.G970D is the most frequent CFTR mutation in Chinese patients with cystic fibrosis.

Authors:  Xinlun Tian; Yaping Liu; Jun Yang; Han Wang; Tao Liu; Wenbing Xu; Xue Li; Yuanjue Zhu; Kai-Feng Xu; Xue Zhang
Journal:  Hum Genome Var       Date:  2016-01-07

5.  Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases.

Authors:  Xiaobei Guo; Keqiang Liu; Yaping Liu; Yusen Situ; Xinlun Tian; Kai-Feng Xu; Xue Zhang
Journal:  Orphanet J Rare Dis       Date:  2018-12-17       Impact factor: 4.123

6.  Liver Failure in a Chinese Cystic Fibrosis Child With Homozygous R553X Mutation.

Authors:  Haiyan Li; Li Lin; Xiaoguang Hu; Changchong Li; Hailin Zhang
Journal:  Front Pediatr       Date:  2019-02-20       Impact factor: 3.418

7.  c.753_754delAG, a novel CFTR mutation found in a Chinese patient with cystic fibrosis: A case report and review of the literature.

Authors:  Yu-Qing Wang; Chuang-Li Hao; Wu-Jun Jiang; Yan-Hong Lu; Hui-Quan Sun; Chun-Yan Gao; Min Wu
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

8.  Novel CFTR mutations in a Korean infant with cystic fibrosis and pancreatic insufficiency.

Authors:  Young June Choe; Jae Sung Ko; Jeong Kee Seo; Jae Jun Han; Jung Ok Shim; Young Yull Koh; Ran Lee; Chang-Seok Ki; Jong-Won Kim; Jung Ho Kim
Journal:  J Korean Med Sci       Date:  2009-12-29       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.